XRTX

+ Watchlist + Portfolio

XORTX Therapeutics Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.73
52-Week Range: $1.59 – $7.05
Market Cap: $3.11M
P/E (TTM): —
EPS (TTM): -2.61
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.15
PEG Ratio: —
Return on Equity: -99.24%
Return on Assets: -29.85%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.59
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-2.58M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.12M

XRTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.76M	$2.42M	$183.83K	$574.93K
Selling, General & Admin	$2.40M	$2.23M	$2.28M	$1.83M
Operating Expenses	$10.29M	$6.05M	$4.12M	$3.26M
Operating Income	-$10.29M	-$6.05M	-$4.12M	-$3.26M
EBITDA	-$10.23M	-$5.91M	-$4.00M	-$3.14M
Pretax Income	-$7.72M	-$2.16M	-$3.31M	-$2.66M
Net Income	-$7.72M	-$2.16M	-$3.31M	-$2.66M
Diluted EPS	-23.54	-5.45	-5.75	-2.80
Diluted Shares	295982	396346	575702	946926

XRTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.43M	$3.45M	$2.47M	$864.51K
Receivables	$81.75K	$60.71K	$17.64K	$80.17K
Current Assets	$10.90M	$4.07M	$2.68M	$1.26M
Total Assets	$12.37M	$5.47M	$4.09M	$2.68M
Current Liabilities	$1.51M	$825.94K	$757.99K	$599.07K
Total Debt	$77.60K	$11.51K	$38.78K	$37.29K
Total Liabilities	$5.38M	$825.94K	$757.99K	$599.07K
Retained Earnings	-$15.70M	-$17.85M	-$21.17M	-$23.82M
Shareholders' Equity	$7.00M	$4.64M	$3.34M	$2.08M
Working Capital	$9.38M	$3.24M	$1.92M	$662.03K

XRTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.17M	-$6.58M	-$3.68M	-$2.77M
Capital Expenditure	-$45.70K	-$46.36K	-$38.92K	-$55.22K
Free Cash Flow	-$8.21M	-$6.63M	-$3.72M	-$2.82M
Depreciation & Amortisation	$58.15K	$139.69K	$117.27K	$112.11K
Stock-Based Compensation	$487.94K	$120.98K	$122.53K	$25.16K
Investing Cash Flow	-$45.70K	-$46.36K	-$38.92K	-$294.95K
Financing Cash Flow	$3.91M	-$361.04K	$2.78M	$1.43M
Net Change in Cash	-$4.30M	-$6.99M	-$938.06K	-$1.64M

XRTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$276.31K	$186.75K	$57.01K	$54.86K	$33.11K	$113.93K
Selling, General & Admin	$477.80K	$465.83K	$392.94K	$495.11K	$621.87K	$260.10K
Operating Expenses	$963.46K	$889.95K	$716.20K	$686.42K	$823.30K	$1.69M
Operating Income	-$963.46K	-$889.95K	-$716.20K	-$686.42K	-$823.30K	-$1.69M
EBITDA	-$937.47K	-$862.32K	-$686.81K	-$657.30K	-$797.45K	-$1.67M
Pretax Income	-$698.67K	-$717.70K	-$649.47K	-$590.46K	-$808.47K	-$1.69M
Net Income	-$698.67K	-$717.70K	-$649.47K	-$590.46K	-$808.47K	-$1.69M
Diluted EPS	-0.93	-0.95	-0.65	—	-0.58	-1.05
Diluted Shares	747420	757649	971298	—	1.39M	1.62M

XRTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.90M	$1.06M	$1.19M	$864.51K	$250.28K	$994.04K
Receivables	$17.25K	$10.86K	$22.09K	$80.17K	$64.63K	$88.09K
Current Assets	$2.10M	$1.26M	$1.36M	$1.26M	$744.42K	$2.44M
Total Assets	$3.50M	$2.74M	$2.81M	$2.68M	$2.14M	$6.18M
Current Liabilities	$757.35K	$711.46K	$837.41K	$599.07K	$860.99K	$679.52K
Total Debt	$15.66K	$80.47K	$59.09K	$37.29K	$15.06K	$0.00
Total Liabilities	$757.35K	$711.46K	$837.41K	$599.07K	$860.99K	$679.52K
Retained Earnings	-$21.87M	-$22.58M	-$23.23M	-$23.82M	-$24.63M	-$26.32M
Shareholders' Equity	$2.74M	$2.03M	$1.97M	$2.08M	$1.28M	$5.50M
Working Capital	$1.35M	$553.07K	$520.07K	$662.03K	-$116.57K	$1.76M

XRTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$643.73K	-$793.52K	-$629.62K	-$701.86K	-$501.36K	-$3.27M
Capital Expenditure	-$3.38K	-$21.82K	-$5.49K	-$24.53K	-$3.79K	-$143.59K
Free Cash Flow	-$647.12K	-$815.34K	-$635.10K	-$726.38K	-$505.15K	-$3.41M
Depreciation & Amortisation	$25.98K	$27.63K	$29.39K	$29.11K	$25.84K	$18.32K
Stock-Based Compensation	$8.97K	$6.95K	$5.12K	$4.12K	$7.82K	$2.13K
Investing Cash Flow	-$3.38K	-$21.82K	-$5.49K	-$264.26K	-$7.92K	-$139.47K
Financing Cash Flow	$67.58K	-$43.44K	$770.88K	$632.53K	-$104.20K	$4.16M
Net Change in Cash	-$579.54K	-$858.79K	$135.78K	-$333.58K	-$613.48K	$750.18K

Market Snapshot

About

XORTX Therapeutics is a pharmaceutical company developing therapies to treat progressive kidney disease. The company focuses on xanthine oxidase inhibitors and other compounds to address acute and chronic kidney conditions. XORTX is advancing its pipeline through clinical trials targeting autosomal dominant polycystic kidney disease and other renal disorders.